OBJECTIVE: Type I IFNs have recently been implicated in autoantibody-mediated diseases such as SLE. As half the RA patients display a type I IFN(high) signature, we investigated in a pilot study if type I IFN determines the autoantibody response in RA. METHODS: Serum and peripheral blood cells were obtained from 52 RA patients, with paired samples before and after infliximab treatment in 21 patients. Additional samples were collected from 8 anti-citrullinated protein antibody (ACPA)-positive individuals without arthritis and from 10 ACPA-negative healthy controls. The type I IFN signature was determined by peripheral blood cell gene expression analysis and quantitative RT-PCR. ACPA IgG and IgM, RF IgM, anti-nucleosome IgM and anti-dsDNA were measured by ELISA. RESULTS: The type I IFN signature was not related to the presence and titers of ACPA and RF during active disease. TNF blockade induced a similar rise of ANAs, and a similar decrease in RF titers in both groups. ACPA IgG and IgM levels appeared to be down-modulated only in the type I IFN(low) group. These changes were independent of the changes in type I IFN response gene activity after TNF blockade. Furthermore, the ACPA response in individuals without arthritis and inflammation was not related to an increase of type I IFN. CONCLUSIONS: In this explorative study, type I IFN signature does not appear to have a major impact on the humoral autoimmune response in RA. Replication of these data remains warranted.
OBJECTIVE: Type I IFNs have recently been implicated in autoantibody-mediated diseases such as SLE. As half the RApatients display a type I IFN(high) signature, we investigated in a pilot study if type I IFN determines the autoantibody response in RA. METHODS: Serum and peripheral blood cells were obtained from 52 RApatients, with paired samples before and after infliximab treatment in 21 patients. Additional samples were collected from 8 anti-citrullinated protein antibody (ACPA)-positive individuals without arthritis and from 10 ACPA-negative healthy controls. The type I IFN signature was determined by peripheral blood cell gene expression analysis and quantitative RT-PCR. ACPA IgG and IgM, RF IgM, anti-nucleosome IgM and anti-dsDNA were measured by ELISA. RESULTS: The type I IFN signature was not related to the presence and titers of ACPA and RF during active disease. TNF blockade induced a similar rise of ANAs, and a similar decrease in RF titers in both groups. ACPA IgG and IgM levels appeared to be down-modulated only in the type I IFN(low) group. These changes were independent of the changes in type I IFN response gene activity after TNF blockade. Furthermore, the ACPA response in individuals without arthritis and inflammation was not related to an increase of type I IFN. CONCLUSIONS: In this explorative study, type I IFN signature does not appear to have a major impact on the humoral autoimmune response in RA. Replication of these data remains warranted.
Authors: Jorge L Cervantes; Esther Oak; John Garcia; Hongfei Liu; Paolo A Lorenzini; Deepika Batra; Arvind Chhabra; Juan C Salazar; Xavier Roca Journal: Tuberculosis (Edinb) Date: 2019-05-03 Impact factor: 3.131
Authors: Hennie G Raterman; Saskia Vosslamber; Sander de Ridder; Michael T Nurmohamed; Willem F Lems; Maarten Boers; Mark van de Wiel; Ben A C Dijkmans; Cornelis L Verweij; Alexandre E Voskuyl Journal: Arthritis Res Ther Date: 2012-04-27 Impact factor: 5.156
Authors: Tamarah D de Jong; Joyce Lübbers; Samina Turk; Saskia Vosslamber; Elise Mantel; Hetty J Bontkes; Conny J van der Laken; Johannes W Bijlsma; Dirkjan van Schaardenburg; Cornelis L Verweij Journal: Arthritis Res Ther Date: 2016-07-13 Impact factor: 5.156
Authors: Lisa Gm van Baarsen; Carla A Wijbrandts; François Rustenburg; Tineke Cantaert; Tineke Ctm van der Pouw Kraan; Dominique L Baeten; Ben Ac Dijkmans; Paul P Tak; Cornelis L Verweij Journal: Arthritis Res Ther Date: 2010-01-22 Impact factor: 5.156
Authors: Marit Stockfelt; Anna-Carin Lundell; Merete Lund Hetland; Mikkel Østergaard; Till Uhlig; Marte Schrumpf Heiberg; Espen A Haavardsholm; Michael T Nurmohamed; Jon Lampa; Dan Nordström; Kim Hørslev Petersen; Bjorn Gudbjornsson; Gerdur Gröndal; Jonathan Aldridge; Kerstin Andersson; Kaj Blennow; Henrik Zetterberg; Ronald van Vollenhoven; Anna Rudin Journal: Arthritis Res Ther Date: 2021-07-13 Impact factor: 5.156
Authors: Javier Rodríguez-Carrio; Banesa de Paz; Patricia López; Catuxa Prado; Mercedes Alperi-López; Francisco Javier Ballina-García; Ana Suárez Journal: PLoS One Date: 2014-01-21 Impact factor: 3.240